{"title":"Synthesis and biological activities of flavonoid sulfamates as steroid sulfatase inhibitors","authors":"Hatem A Hejaz, Atul Purohit, Barry V L Potter","doi":"10.55522/jmpas.v12i5.5576","DOIUrl":null,"url":null,"abstract":"Synthesis of potent flavonoid sulfamate inhibitors of the enzyme steroid sulfatase (STS), a topical target in treating postmenopausal women with hormone-dependent breast cancer, is described in the current article. Novel compounds were examined for estrone sulfatase (E1-STS) inhibition in intact MCF-7 breast cells. The strategies adopted to develop STS inhibitors which, while active in vivo, are devoid of any estrogenicity that would limit their use for breast cancer therapy (e.g. estrone 3-O-sulfamate, EMATE), were broadly successful. Several molecules of flavonoid sulfamates were synthesized that potentially possess both aromatase and steroid sulfatase inhibitory properties. The isoflavane-4',7-O,O-bis-sulfamate (equol bis-sulfamate) and flavone-6,4'-O,O-bis-sulfamate were found to be the most potent inhibitors of all the flavonoid sulfamate analogs in vitro, inhibiting STS by about 99% at 0.1μM in MCF-7 cells. Some of these flavonoid sulfamates were also found to be active against both enzymes’ STS and aromatase (e.g., 5-hydroxy-7-methoxyflavone-4'-O-sulfamate, 5-hydroxy-flavone-4',7-O,O-bis-sulfamate, and 5,7-dihydroxy flavanone-4'-O-sulfamate), thus demonstrating the novel concept of a dual inhibitor. The availability of flavonoid sulfamates as STS inhibitors may enable to use of them as a therapy in the treatment of breast cancer.","PeriodicalId":16445,"journal":{"name":"Journal of Medical pharmaceutical and allied sciences","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical pharmaceutical and allied sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55522/jmpas.v12i5.5576","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Synthesis of potent flavonoid sulfamate inhibitors of the enzyme steroid sulfatase (STS), a topical target in treating postmenopausal women with hormone-dependent breast cancer, is described in the current article. Novel compounds were examined for estrone sulfatase (E1-STS) inhibition in intact MCF-7 breast cells. The strategies adopted to develop STS inhibitors which, while active in vivo, are devoid of any estrogenicity that would limit their use for breast cancer therapy (e.g. estrone 3-O-sulfamate, EMATE), were broadly successful. Several molecules of flavonoid sulfamates were synthesized that potentially possess both aromatase and steroid sulfatase inhibitory properties. The isoflavane-4',7-O,O-bis-sulfamate (equol bis-sulfamate) and flavone-6,4'-O,O-bis-sulfamate were found to be the most potent inhibitors of all the flavonoid sulfamate analogs in vitro, inhibiting STS by about 99% at 0.1μM in MCF-7 cells. Some of these flavonoid sulfamates were also found to be active against both enzymes’ STS and aromatase (e.g., 5-hydroxy-7-methoxyflavone-4'-O-sulfamate, 5-hydroxy-flavone-4',7-O,O-bis-sulfamate, and 5,7-dihydroxy flavanone-4'-O-sulfamate), thus demonstrating the novel concept of a dual inhibitor. The availability of flavonoid sulfamates as STS inhibitors may enable to use of them as a therapy in the treatment of breast cancer.
合成有效的类黄酮磺胺酸抑制剂的酶类固醇磺胺酶(STS),一个局部目标治疗绝经后妇女激素依赖性乳腺癌,在当前的文章中进行了描述。在完整的MCF-7乳腺细胞中检测了新化合物对雌酮硫酸酯酶(E1-STS)的抑制作用。开发STS抑制剂所采用的策略是广泛成功的,这些抑制剂虽然在体内有活性,但没有任何雌激素原性,这将限制其用于乳腺癌治疗(例如雌酮3- o -氨基磺酸,EMATE)。合成了几种可能同时具有芳香化酶和类固醇磺化酶抑制特性的类黄酮磺酸盐分子。异黄酮-4′,7-O, o -双磺胺酸酯(马酚双磺胺酸酯)和黄酮-6,4′-O, o -双磺胺酸酯是所有类黄酮磺酸类似物的最有效的体外抑制剂,在0.1μM的MCF-7细胞中抑制STS约99%。其中一些类黄酮磺酸盐还被发现对酶的STS和芳香化酶都有活性(例如,5-羟基-7-甲氧基黄酮-4'- o -氨基磺酸盐,5-羟基黄酮-4',7-O, o -双氨基磺酸盐和5,7-二羟基黄酮-4'- o -氨基磺酸盐),从而证明了双重抑制剂的新概念。类黄酮磺酸盐作为STS抑制剂的可用性可能使其成为乳腺癌治疗的一种疗法。